CNS Biomarkers: Monument Targets Schizophrenia, Anxiety And Cognitive Decline

An Interview With Steven Powell

Steven Powell, chair of the board at Cambridge Cognition, talks about the group’s latest spin-off company, Monument Therapeutics.

IV2001_CNS_1499796839_1200.jpg
• Source: Shutterstock

Prior to moving to Belgium a year ago to become CEO of eTheRNA immunotherapies NV, Steven Powell was CEO of Cambridge Cognition, where he remains a non-executive director and chair of the board. Cambridge Cognition recently spun off a new entity – Monument Therapeutics – which aims to use cognitive profiles as a biomarker for patients, to be able to predict how they will respond to a treatment.

Cambridge Cognition uses computerized tests to monitor and assess cognitive function – that primarily look at memory and reaction time...

More from C-Suite Speaks

More from Leadership